Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I XAGE1B long-peptide vaccine plus Hiltonol in pulmonary adenocarcinoma
NL-OMON45223Phase 1Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of poly iclc, XAGE1B synthetic long peptide vaccine and montanide isa-51 in Non-small cell lung cancer adenocarcinoma (NSCLC) and non-small cell lung cancer (NSCLC), sponsored by Leiden University Medical Center. Started Oct 2015; status: active, not recruiting.
02
Drugs
poly iclcXAGE1B synthetic long peptide vaccinemontanide isa-51
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45223.